Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantJH
Janus Henderson Investors
Activity from announced rounds
Activity in this selectionUnited States
Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.
Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.
The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.
- Rounds participated in
- 14
- Confirmed lead rounds
- 0 11 roles undisclosed
- New companies
- 14 First participation on record · 0 follow-on
- Funding in participating rounds
- $2B 14 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
14 in this selectionEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedTriveni Bio
Develops novel antibody treatments for immunological and inflammatory disorders
$65MSeries C
Role not disclosedCalyxo
Develops medical devices for kidney stone treatment and removal
$40MSeries F
Role not disclosedAmbrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
ParticipantPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosedILiAD Biotechnologies
Developing a next-generation pertussis vaccine candidate BPZE1
$115MSeries B
Role not disclosedCesiumAstro
CesiumAstro develops communications technology for space and defense applications.
$470MSeries C
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedThink Bioscience
Develops small molecule drugs for historically challenging drug targets
$55MSeries A
Role not disclosedCaldera Therapeutics
Develops bispecific antibody CLD-423 for inflammatory bowel disease
$37.5MSeries A1
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed